Perspective · 26 Mar 2024
Conference abstractPublished 7 Nov 2016
EB101 vaccine as a dual immunotherapy for preventing and treating Alzheimerandprime;s disease
EuroEspes Biotechnology, Spain EuroEspes Biomedical Research Center, Spain Atlas Pharmaceuticals, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Amyloid-Ã?² immunization has become one of the most promising immunotherapeutic approaches in the prevention and treatment of Alzheimer's disease (AD) hallmarks, especially the use of active immunization strategies with specific conformations of these proteins has yielded promising results in animal models. However, these prototypes have been clinically unsuccessful when preventing neuroinflammation. Therefore, a new paradigm is needed by using new immuneagents against AD-like pathology, a notion supported by our recent successful active immunotherapy results with adjuvant that induce Th2-only while inhibiting without abrogating Th1 immunity. Here, we discuss the obstacles to AÃ?² 1-42 vaccine (EB101) development and the potential benefits of AÃ?² 1-42 delivered in a novel immunogen-adjuvant composed of niosomescontaining sphingosine-1-phosphate (S1P) that induces regardless of the antigen a safe and effective antibody response, while preventing damaging neuroinflammation and ameliorating pathological degeneration. Chronic administration of EB101 to AD transgenic mice led to a dual immunotherapeutical effect as preventive, before AÃ?² plaques development and treatment action by the significant reduction in amyloid-Ã?² accumulation in both cortical and hippocampal regions when measured by confocal imaging and immunohistochemistry. Therefore, immunization with EB101 has proven neuroprotective effect to prevent and reverse AD-like neuropathology in a significant manner by halting disease progression without developing behavioral deficits in transgenic mice.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 21 May 2018
Integration of omics data to understand Alzheimerandprime;s disease
Conference abstract · 7 Nov 2016
Pentagenic haplotype-related cholesterolemic phenotype in Alzheimerandprime;s disease
Conference abstract · 7 Nov 2016
Validation and characterization of 3xTg (APP/Bin1/COPS5) mice as a new neuropathological model of Alzheimerandprime;s disease
Conference abstract
3D neural stem cell models of Alzheimerandprime;s disease
More from this journal
The newest in Human Genetics & Embryology.
Commentary · 29 Nov 2025
Chromosomal Abnormalities: Impact Across Human Health
Commentary · 29 Nov 2025
Down Syndrome: Complexities, Comorbidities, and Care
Brief report · 29 Nov 2025
Turner Syndrome: Comprehensive, Lifelong, Holistic Care
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalHuman Genetics & Embryology
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Ivan Carrera”
- BylineArticles whose byline prints “Lucia Fernandez-Novoa”
- BylineArticles whose byline prints “Ivan Tellado”
- BylineArticles whose byline prints “Carmen Vigo”
- BylineArticles whose byline prints “Ramon Cacabelos”

